Drug Trial Radar · NCT05475106
Pilot Study of Neoantigen Peptides and Leukine for the Treatment of Neoplasms
Last checked: Nov 20, 2026Latest source record: Mar 6, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
100
Planned (sponsor's estimate)
Start
May 12, 2022
Primary completion
Nov 25, 2025
Study completion Jun 20, 2026
Sponsor
- Lead sponsor
- Instituto de Medicina RegenerativaIndustry
- Sponsor type
- Industry
- First posted
- Jul 26, 2022
Design
- Study type
- Interventional
- Phase
- Early phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 16 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The present study is a pilot clinical trial using personalized neoantigen peptide vaccines with the addition of Leukine (Sargramostim), in patients with different types of cancer.
Conditions
- Neoplasms
Interventions
Neoantigen PeptidesBiological
Patients will receive intradermal injection of individualized neoantigen peptides vaccine at a dose of \~500ug per peptide once a week for 4 weeks, and every month for 5 months after that.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from Baseline in WBC countTime frame: Baseline, 2, 6, 12 months
- Change from Baseline in RBC countTime frame: Baseline, 2, 6, 12 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Instituto de Medicina Regenerativa
Tijuana, Estado de Baja California, Mexico · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.